Anne Beaufour Net Worth

Anne Beaufour has an estimated net worth of $3.9 billion, according to Forbes Real-Time Billionaires, Anne Beaufour profile (figures as of October 20, 2026). That is up from $2.9 billion in 2019.

Anne Beaufour is a French businesswoman and one of the heirs to Ipsen, the French pharmaceutical company that sells more than 25 drugs in 115 countries. She was born on August 8, 1963, in Neuilly-sur-Seine, outside Paris.

She is the daughter of Albert Beaufour, who died in 2000, and the granddaughter of Dr. Henri Beaufour, who founded the Beaufour laboratories that became Ipsen. She holds a degree in geology from the University of Paris-Sud in Orsay. In 1999 she married Michel Audibert. Her grandfather was a doctor, and the pharmaceutical business he started has stayed under the family's control for nearly a century, passing through three generations.

Beaufour sits on the board of directors of Ipsen and of Mayroy, the holding company that controls Ipsen. Through those seats she has a direct voice in how the family company is run, alongside her brother Henri, who shares control of the group with her.

How Anne Beaufour got her money

Henri Beaufour founded the family company in 1929. It grew over the decades into Ipsen, a global drugmaker. When Albert Beaufour died in 2000, the family's 76% stake in Ipsen was divided among his three children: Anne, her brother Henri and her sister Véronique. The split of that stake shaped the ownership of the company for the next two decades, as each sibling made their own choice about whether to stay invested.

Véronique later sold her stake of about 6%. Anne and Henri kept theirs, and together they control 52% of Ipsen, which generated revenue of more than $3.4 billion in 2022. Anne's fortune therefore rests on her share of that controlling stake, and it moves with the value of Ipsen on the stock market and with the success of its medicines.

How Forbes has valued Anne Beaufour

Forbes valued Beaufour at $2.9 billion in 2019. Her figure dropped to $1 billion in 2020, then recovered to $2 billion in 2021, $2.6 billion in 2022 and $2.7 billion in both 2023 and 2024.

It rose to $2.9 billion in 2025 and jumped to $4.5 billion on the 2026 World's Billionaires List, her highest figure. As of October 20, 2026, the Forbes real-time billionaires tracker showed $3.9 billion. The large jump in 2026 lifted her to the highest figure of her record, and her stake makes her one of the main owners of a major listed French drugmaker. Her figures over the years have tracked the shares of Ipsen closely, since nearly all of her fortune is tied to the company.